Skip to main content
Skip to content
Case File
dc-4441947Court Unsealed

Settlement Agreement

Date
April 19, 2018
Source
Court Unsealed
Reference
dc-4441947
Pages
4
Persons
0
Integrity
No Hash Available

Summary

SETTLEMENT AGREEMENT BETWEEN THE UNITED STATES OF AMERICA AND DR. MICHAEL T. SCHULENBERG, M.D. PARTIES This Settlement Agreement ("Agreement") is entered into between the United States of America, acting through the United States Attorney' s Office for the District of Minnesota and the Drug Enforcement Administration (the "United States"), and Michael T. Schulenberg ("Dr. Schulenberg"), to settle civil claims asserted by the United States under the Controlled Substances Act, 21 U .S.C. §§ 827-82

Ask AI about this document

Search 264K+ documents with AI-powered analysis

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
SETTLEMENT AGREEMENT BETWEEN THE UNITED STATES OF AMERICA AND DR. MICHAEL T. SCHULENBERG, M.D. PARTIES This Settlement Agreement ("Agreement") is entered into between the United States of America, acting through the United States Attorney' s Office for the District of Minnesota and the Drug Enforcement Administration (the "United States"), and Michael T. Schulenberg ("Dr. Schulenberg"), to settle civil claims asserted by the United States under the Controlled Substances Act, 21 U .S.C. §§ 827-829 and 842. PREAMBLE Dr. Schulenberg is a licensed physician in the State of Minnesota registered I. with the Drug Enforcement Administration ("DEA") as a practitioner authorized to dispense Schedule 2-5 controlled substances. Dr. Schulenberg' s DEA Registration Number is 2. The United States contends that on April 14, 2016, Dr. Schulenberg prescribed Schedule 2 controlled substances in the name of an individual, knowing that the controll ed substances were intended to be used by another individual, in violation of the Controlled Substances Act and its implementing regulations, 21 U.S .C. §§ 827(b), 829, 842(a)(l) and 21 C.F.R. §§ 1306.04 and 1306.05. The alleged violations of the Controlled Substances Act and implementing federal regulations alleged to have occurred above are hereinafter referred to as "the Covered Conduct." 3. The United States contends that it has civil claims for penalties against Dr. Schulenberg for the Covered Conduct. 4. In order to avoid the delay, uncertainty, inconvenience, and expense of protracted litigation of these claims, the United States and Dr. Schulenberg reach a full and final settlement of the Covered Conduct as set forth below. 5. This Settlement Agreement is made in compromise of disputed claims. This Settlement Agreement is neither an admission of facts nor liability by Dr. Schulenberg, nor a concession by the United States that its claims are not well-founded . TERMS AND CONDITIONS In consideration of the mutual promises, covenants, and obligations set forth below, and for good and valuable consideration as stated herein, the United States and Dr. Schulenberg agree as follows: 6. Monetary Payment. Dr. Schulenberg agrees to pay to the United States the sum of Thirty Thousand Dollars ($30,000.00) as settlement of the United States' claims for the Covered Conduct (the " Settlement Amount"). The Settlement Amount shall be paid within thirty days of the effective date of this agreement or within thirty days of receipt by Dr. Schulenberg or its designee of instructions for payment provided by the United States Attorney's Office for the District of Minnesota, whichever date shall occur later. 7. l\1emorandum of Agreement. Dr. Schulenberg agrees to enter into the Memorandum of Agreement ,vith the Drug Enforcement Administration, attached hereto as Exhibit A to this agreement, and abide by all requirements therein. 8. Release by the United States. The United States, on behalf of itself, its officers, agents, agencies, and departments, releases Dr. Schulenberg from any civil or administrative monetary claims the United States has or may have under 21 U.S.C. § 842 or the implementing regulations at 21 C.F.R. § 1301 , 1304, and 1305, for the Covered Conduct. This release hy the United States is subject to the exclusions in Paragraph 9 of this Agreement and is made in consideration of the obligations of Dr. Schulenberg as set forth in this Agreement and the Memorandum of Agreement attached hereto and incorporated into this Agreement. The Release by the United States is also conditioned upon Dr. Schulenberg' s payment in full of the Settlement Amount on the due date specified herein. 9. Release Exclusions. Specifically reserved and excluded from the scope and terms of the Releases by the United States in paragraph 8 of this Agreement are any and all of the following : a. Any civil, criminal, or administrative claims arising under Title 26 of the United States Code ("the Internal Revenue Code"); b. Any criminal liability; c. Any liability to the United States or its agencies for any conduct other than the Covered Conduct; and d. Any liability based upon obligations created by this Agreement and the attached Memorandum of Agreement. 10. Agreement Not to Revoke or Suspend Registration. The United States further agrees not to revoke or suspend DEA Registration Number , now held by Dr. Schulenberg, as a result of the Covered Conduct, unless as provided in the Memorandum of Agreement in Exhibit A. 11. Release by Dr. Schulenberg. Dr. Schulenberg releases the United States, its agencies , employees, servants and agents from any claims (including attorney ' s fees , costs, and expenses of every kind and however denominated) which Dr. Schulenberg has 2 - - - -- - - - -- --- . --- - asserted, could have asserted, or may assert in the future against the United States, its agencies, employees, servants, and agents, related to the Covered Conduct and the United States ' investigation and prosecution thereof. 12. Costs and Attorney's Fees. The United States and Dr. Schulenberg will each bear their own legal and other costs incurred in connection with this matter, including the preparation and performance of this Agreement. 13 . Law Governing Agreement; Jurisdiction and Venue. This Agreement is governed by the laws of the United States. The United States and Dr. Schulenberg agree that the exclusive jurisdiction and venue for any dispute arising between them under this Agreement will be the United States District Court for the District of Minnesota. 14. Complete Agreement; Amendments. This Agreement constitutes the complete agreement between the United States and Dr. Schulenberg. This Agreement may not be amended except by written consent of the United States and Dr. Schulenberg. 15. Execution of Agreement. This Agreement may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same agreement. 16. Effective Date. This Agreement is effective on the date of signature of the last signatory party to the Agreement. [Signatures on follo wing page] 3 --------- FOR THE UNITED STATES OF AMERICA: DATED: /t&,/rr Lf GREGORY G. BROOKER United States Attorney #392645) Assistant U.S. Attorney 600 U.S. Courthouse 300 S. Fourth Street Minneapolis, MN 5 5415 (612) 665-5600 [email protected] FOR MICHAEL T. SCHULENBERG: DATED: '/ /1<./1t I I Michael T. Schulenberg, M. Fairview Clinics - New Bri 11 51 Silver Lake Road NW DATED: ~ 1(r~ /~< ~ Thomas B. Heffelfinger Best & Flanagan 60 South 6th Street Ste 2700 Minneapolis, MN 55402 612-339-7121 aco1mers@bestla w .com 4 ·--·--- -- ·

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.